ArticleDermatology (Basel, Switzerland)2026
Evaluation of the Contribution of Repeat Total Body Photography for the Early Diagnosis of Melanoma.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Early detection of cutaneous melanoma is crucial, as prognosis is strongly determined by Breslow thickness. Total body photography (TBP) is increasingly used in high-risk populations, yet optimal surveillance strategies remain undefined. In our study, we aimed to evaluate how different follow-up approaches, including those incorporating TBP at varying frequencies, influence the early diagnosis of melanoma, as measured by Breslow thickness.
methodsThis retrospective cohort study included adult patients diagnosed with primary cutaneous melanoma at Rabin Medical Center between 2020 and 2025. Melanomas were classified into four groups according to the clinical setting at diagnosis: non-high-risk clinics, first visit to a high-risk clinic before TBP, high-risk follow-up with prior TBP only, and high-risk follow-up with both prior and repeat TBP on the day of diagnosis. Demographic, clinical, and histopathologic data were extracted. Differences in Breslow thickness were analyzed using analysis of covariance, and invasive versus in situ melanoma rates were assessed using multivariable logistic regression.
resultsA total of 282 melanomas from 249 patients were analyzed. Melanomas diagnosed in non-high-risk clinics were significantly thicker than those diagnosed in high-risk clinics (adjusted mean Breslow difference: 0.78 mm). Surveillance strategy was associated with invasiveness: invasive melanoma rates were highest in non-high-risk clinics (52%), followed by first visit to high-risk clinic (39%), patients with prior TBP only (34%), and lowest in patients diagnosed during repeat TBP (20%; overall model p = 0.03). Overall Breslow thickness did not differ significantly between melanomas diagnosed during visits with prior TBP alone and those diagnosed during repeat TBP.
conclusionHigh-risk melanoma clinics incorporating TBP are associated with earlier melanoma detection and lower rates of invasive disease. Repeated TBP was associated with lower rate of invasive melanoma compared with baseline TBP and manual comparison on the day of diagnosis. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.